Current Topics in Nonclinical Drug Development

<p>The second volume in the <i>CURRENT TOPICS IN NONCLINICAL DRUG DEVELOPMENT SERIES</i> explores the critical issues and current topics in nonclinical drug development. This second volume covers individual topics and strategies in drug development from compound characterization to drug registration. Written by a variety of experts in the field recent and rapid advances in technologies and associated changes in regulatory guidance are discussed.</p><p>Select topics include:</p><ul> <li>Evolution of Artificial Intelligence (AI) technologies and the impact on toxicologic pathology.</li> <li>Current approaches to carcinogenicity testing.</li> <li>Predicting drug-drug interactions.</li> <li>Current understanding of idiosyncratic drug reaction.</li> <li>Assessing cardiovascular risks beyond QT interval.</li> <li>Use of 3D cell cultures in toxicology and ADME.</li> <li>Development of small molecule-antibody complexes.</li> <li>Differentiating adverse from non-adverse findings in nonclinical studies.</li> </ul><p><b><i>Current Topics in Nonclinical Drug Development: Volume 2</i></b> will aid toxicologists toxicologic pathologists consultants regulators study directors and nonclinical scientists dealing with day-to-day issues encountered in drug development and assist in formulating strategies for resolution of these issues. In addition the book will be a valuable reference for academicians and graduate students pursuing research related to nonclinical drug development.</p>